TMA 1
TMA has been designed to facilitate identification of markers differentially expressed in primary mesothelioma lesions as well as metastatic lesions. Samples from 40 patients have been incorporated: 36 patients have tissue cores from the primary lesion only, 3 patients have tissue cores from a metastatic lesion only, and 1 patient has tissue cores from both the primary and metastatic lesions. Of the patients with available clinical annotation, 97% are male and 3% are female, and racial breakdown is as follows: 57% white, 3% black, and 39% unknown. Pathologic site and histologic type for annotated cases is shown.
| Histologic Type | Cases |
|---|---|
| Biphasic | 10 |
| Epithelial/Epitheliod | 20 |
| Sarcomatoid | 3 |
| Multicystic | 1 |
| Papillary | 2 |
| Benign Fibrous | 2 |
| Fibrocystic | 1 |
| Desmoplastic | 1 |
| Benign | 4 |
| Malignant | 36 |
| Primary | 36 |
| Metastatic | 3 |
| Primary/Metastatic | 1 |
| Pathologic Site | Cases |
|---|---|
| Pleura Not Specified | 25 |
| Peritoneum | 13 |
| Other | 2 |
TMA 2
TMA has been designed to facilitate identification of markers differentially expressed in primary mesothelioma lesions as well as metastatic lesions. Samples from 12 patients have been incorporated. Pathologic site and histologic type for annotated cases is shown.
| Histologic Type | Cases |
|---|---|
| Biphasic | 9 |
| Epithelial/Epitheliod | 39 |
| Sarcomatoid | 5 |
| Multicystic | 0 |
| Papillary | 0 |
| Benign Fibrous | 0 |
| Fibrocystic | 0 |
| Desmoplastic | 1 |
| Pathologic Site | Cases |
|---|---|
| Pleura Not Specified | 49 |
| Peritoneum | 3 |
| Other | 2 |
TMA 3
TMA has been designed to facilitate identification of markers differentially expressed in primary mesothelioma lesions as well as metastatic lesions. Samples from 9 patients have been incorporated. Pathologic site and histologic type for annotated cases is shown.
| Histologic Type | Cases |
|---|---|
| Biphasic | 9 |
| Epithelial/Epitheliod | 39 |
| Sarcomatoid | 5 |
| Multicystic | 0 |
| Papillary | 0 |
| Benign Fibrous | 0 |
| Fibrocystic | 0 |
| Desmoplastic | 1 |
| Pathologic Site | Cases |
|---|---|
| Pleura Not Specified | 49 |
| Peritoneum | 3 |
| Other | 2 |
TMA 4
TMA has been designed to facilitate identification of markers differentially expressed in primary mesothelioma lesions as well as metastatic lesions. Samples from 30 patients have been incorporated. Pathologic site and histologic type for annotated cases is shown.
| Histologic Type | Cases |
|---|---|
| Biphasic | 9 |
| Epithelial/Epitheliod | 39 |
| Sarcomatoid | 5 |
| Multicystic | 0 |
| Papillary | 0 |
| Benign Fibrous | 0 |
| Fibrocystic | 0 |
| Desmoplastic | 1 |
| Pathologic Site | Cases |
|---|---|
| Pleura Not Specified | 49 |
| Peritoneum | 3 |
| Other | 2 |
TMA 1 RPCCC
TMA has been designed to facilitate identification of markers differentially expressed in primary mesothelioma lesions as well as metastatic lesions. Samples from 56 patients have been incorporated. Pathologic site and histologic type for annotated cases is shown.
| Histologic Type | Cases |
|---|---|
| Biphasic | 10 |
| Epithelial/Epitheliod | 33 |
| Sarcomatoid | 3 |
| Multicystic | 1 |
| Papillary | 1 |
| Benign Fibrous | 0 |
| Fibrocystic | 0 |
| Desmoplastic | 0 |
| Benign | 0 |
| Malignant | 56 |
| Primary | 24 |
| Metastatic | 3 |
| Primary/Metastatic |
| Pathologic Site | Cases |
|---|---|
| Pleura Not Specified | 37 |
| Peritoneum | 9 |
| Other | 10 |